We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

143 hedge funds and large institutions have $347M invested in Karyopharm Therapeutics in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 46 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 17

11% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 46

7% more funds holding

Funds holding: 134 → 143 (+9)

4% more capital invested

Capital invested by funds: $334M → $347M (+$12.6M)

0.29% less ownership

Funds ownership: 5.07% → 4.78% (-0.29%)

55% less call options, than puts

Call options by funds: $4.62M | Put options by funds: $10.3M

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
143
Holders Change
+9
Holders Change %
+6.72%
% of All Funds
2.2%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
29
Increased
51
Reduced
46
Closed
17
Calls
$4.62M
Puts
$10.3M
Net Calls
-$5.68M
Net Calls Change
+$171K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$10.1M
2
FCM
Frontier Capital Management
Massachusetts
+$3.87M
3
CSS
Cubist Systematic Strategies
Connecticut
+$3.11M
4
CWG
C WorldWide Group
Denmark
+$1.99M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$16.7M
2
Morgan Stanley
Morgan Stanley
New York
-$5.5M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$4.35M
4
RCMNY
Rubric Capital Management (New York)
New York
-$3.94M
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$3.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$1.96M +$404K +4,056 +25%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.91M -$33K -331 -2%
PPA
28
Parametric Portfolio Associates
Washington
$1.78M -$104K -1,041 -5%
JGC
29
J. Goldman & Co
New York
$1.76M +$1.44M +14,435 +375%
Jennison Associates
30
Jennison Associates
New York
$1.74M +$4.38K +44 +0.2%
UBS Group
31
UBS Group
Switzerland
$1.72M -$2.27M -22,766 -56%
Bank of America
32
Bank of America
North Carolina
$1.64M +$126K +1,263 +8%
HF
33
HRT Financial
New York
$1.6M +$1.65M +16,555 New
BC
34
Birchview Capital
Vermont
$1.58M – – –
Citadel Advisors
35
Citadel Advisors
Florida
$1.47M +$53.9K +541 +4%
TI
36
Trexquant Investment
Connecticut
$1.42M +$1.23M +12,312 +510%
Tudor Investment Corp
37
Tudor Investment Corp
Connecticut
$1.34M +$104K +1,040 +8%
Jane Street
38
Jane Street
New York
$1.33M +$1.19M +11,921 +631%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$1.3M +$1.34M +13,437 New
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$1.27M +$1.31M +13,159 New
GCP
41
GSA Capital Partners
United Kingdom
$1.23M +$99.5K +998 +8%
Allianz Asset Management
42
Allianz Asset Management
Germany
$1.21M +$360K +3,610 +41%
Charles Schwab
43
Charles Schwab
California
$1.21M – – –
Barclays
44
Barclays
United Kingdom
$1.17M +$328K +3,291 +37%
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$1.13M +$1.17M +11,737 New
Swiss National Bank
46
Swiss National Bank
Switzerland
$961K +$118K +1,186 +14%
AA
47
AlphaCentric Advisors
Puerto Rico
$900K +$26.5K +266 +3%
Squarepoint
48
Squarepoint
New York
$799K +$826K +8,285 New
Group One Trading
49
Group One Trading
Illinois
$772K +$488K +4,898 +157%
AllianceBernstein
50
AllianceBernstein
Tennessee
$745K – – –
1
2
3 4 5

KPTI Hedge Fund Activity: Q4 2021 in Review

143 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2021, worth a combined $347M — up 3.8% from $334M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KPTI positions and 17 closed out — a net gain of 12 holders — while 51 added to existing stakes and 46 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $10.1M. The largest seller was State Street, cutting an estimated $16.7M.

  • 143 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2021, up from 134 in Q3 2021.
  • Funds reported $347M of Karyopharm Therapeutics stock for Q4 2021, up 3.8% quarter-over-quarter.
  • 29 funds opened new Karyopharm Therapeutics positions in Q4 2021 and 17 closed out, a net change of +12 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $10.1M added.
  • The largest Karyopharm Therapeutics seller in Q4 2021 was State Street, an estimated $16.7M sold.

Based on aggregated 13F filings for Q4 2021.